iSpecimen Q2 revenue down 31% to $1.63M; net loss widens to $3.5M

iSpecimen Inc.

2023-Q2 EPS reported -$0.66 revenue$4,575,339

Revenue of $1.63M (Q2 2023), down 31% YoY from $2.34M; net loss $3.5M ($0.39 per share) vs $2.6M ($0.30) in Q2 2022.
Cash + investments $8.2M at June 30, down from $15.3M at Dec 31, 2022 due to operating spend and technology investments.
Unique customer organizations up 22% YoY to 534; supplier organizations up 7.5% to 230.
CEO cites industry-wide funding slowdown; backlog increased in Q2, expects stronger Q3 2023 results.
New growth initiatives: sequencing pilot complete, embedded coordinators at supplier sites, remnant line reboot.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

iSpecimen Inc. reported the six months ended June 30, 2023 results: revenue approximately $4.6 million, net income approximately $5.9 million, EPS $(0.66) per share.

Period: the six months ended June 30, 2023
Revenue: approximately $4.6 million
Net income: approximately $5.9 million
EPS: $(0.66) per share
Result: reported results

Exact text from the filing

both our top and bottom-line results,” concluded Curley. Q2 2023 Financial Results & Recent Operational Highlights · Revenue of $1.63 million for the three month period and $4.6 million for the six month period of 2023 compared to $2.34 million for the three month period and $4.9 million for the six month period of 2022. · Unique supplier organizations under

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

iSpecimen Inc. reported second quarter of 2023 results: revenue approximately $1.63 million, net income approximately $3.5 million, EPS $(0.39) per share.

Period: second quarter of 2023
Revenue: approximately $1.63 million
Net income: approximately $3.5 million
EPS: $(0.39) per share
Result: reported results

Exact text from the filing

supplier and customer base, we expect to build both our top and bottom-line results,” concluded Curley. Q2 2023 Financial Results & Recent Operational Highlights · Revenue of $1.63 million for the three month period and $4.6 million for the six month period of 2023 compared to $2.34 million for the three month period and $4.9 million for the six month period of

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

iSpecimen Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-086624

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.